Compare OTLY & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OTLY | TECX |
|---|---|---|
| Founded | 1994 | 2019 |
| Country | Sweden | United States |
| Employees | N/A | 51 |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.1M | 393.0M |
| IPO Year | 2021 | N/A |
| Metric | OTLY | TECX |
|---|---|---|
| Price | $11.29 | $24.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $15.50 | ★ $80.40 |
| AVG Volume (30 Days) | 78.7K | ★ 522.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.52 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.25 | $13.70 |
| 52 Week High | $18.84 | $27.21 |
| Indicator | OTLY | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 61.79 |
| Support Level | $10.25 | $16.53 |
| Resistance Level | $12.29 | $26.24 |
| Average True Range (ATR) | 0.73 | 1.94 |
| MACD | -0.03 | 0.17 |
| Stochastic Oscillator | 27.24 | 96.78 |
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.